Lars Riedemann
Overview
Explore the profile of Lars Riedemann including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
1016
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Mathias R, Vasey B, Chalkidou A, Riedemann L, Melvin T, Gilbert S
Nat Med
. 2025 Feb;
31(2):370-375.
PMID: 39905271
No abstract available.
2.
Riedemann L, Labonne M, Gilbert S
NPJ Digit Med
. 2024 Nov;
7(1):339.
PMID: 39604549
No abstract available.
3.
Stern A, Bronneke J, Debatin J, Hagen J, Matthies H, Patel S, et al.
Lancet Digit Health
. 2022 Feb;
4(3):e200-e206.
PMID: 35216754
In 2019, Germany passed the Digital Healthcare Act, which, among other things, created a "Fast-Track" regulatory and reimbursement pathway for digital health applications in the German market. The pathway explicitly...
4.
Burth S, Ohmann M, Kronsteiner D, Kieser M, Low S, Riedemann L, et al.
J Neurooncol
. 2021 Mar;
152(3):483-490.
PMID: 33674992
Purpose: Patients with glioblastoma (GBM) or brain metastases (MET) and atrial fibrillation (AF) might be at an increased risk of intracranial hemorrhage (ICH) due to anticoagulation (AC). Our aim was...
5.
Berghoff A, Breckwoldt M, Riedemann L, Karimian-Jazi K, Loew S, Schlieter F, et al.
Neurooncol Adv
. 2020 Jul;
2(1):vdaa038.
PMID: 32642693
Background: Salvage treatment for recurrent brain metastases (BM) of solid cancers is challenging due to the high symptomatic burden and the limited local treatment options. Methods: Patients with recurrent BM...
6.
Seano G, Nia H, Emblem K, Datta M, Ren J, Krishnan S, et al.
Nat Biomed Eng
. 2019 Apr;
3(3):230-245.
PMID: 30948807
The compression of brain tissue by a tumour mass is believed to be a major cause of the clinical symptoms seen in patients with brain cancer. However, the biological consequences...
7.
Berberich A, Hielscher T, Kickingereder P, Winkler F, Druschler K, Riedemann L, et al.
Int J Radiat Oncol Biol Phys
. 2018 Aug;
102(5):1472-1480.
PMID: 30071292
Purpose: Because treatment options at progression are limited for patients with glioma, accuracy in definition of progression is pivotal. Clinically asymptomatic, newly detected, nonmeasurable, speckled contrast-enhancing lesions (SCEs) without immediate...
8.
Bruns O, Bischof T, Harris D, Franke D, Shi Y, Riedemann L, et al.
Nat Biomed Eng
. 2017 Nov;
1.
PMID: 29119058
For imaging, the short-wavelength infrared region (SWIR; 1000-2000 nm) provides several advantages over the visible and near-infrared regions: general lack of autofluorescence, low light absorption by blood and tissue, and...
9.
Wang X, Valls A, Schermann G, Shen Y, Moya I, Castro L, et al.
Dev Cell
. 2017 Sep;
42(5):462-478.e7.
PMID: 28867486
Vascular endothelial growth factor (VEGF) is a major driver of blood vessel formation. However, the signal transduction pathways culminating in the biological consequences of VEGF signaling are only partially understood....
10.
Kloepper J, Riedemann L, Amoozgar Z, Seano G, Susek K, Yu V, et al.
Proc Natl Acad Sci U S A
. 2016 Apr;
113(16):4476-81.
PMID: 27044098
Inhibition of the vascular endothelial growth factor (VEGF) pathway has failed to improve overall survival of patients with glioblastoma (GBM). We previously showed that angiopoietin-2 (Ang-2) overexpression compromised the benefit...